Issues in the management of acute agitation: How much current guidelines consider safety?

Frontiers in Psychiatry

Volumn 4, Issue MAY, 2013, Pages

  Pacciardi, Bruno ^a   Mauri, Mauro ^a   Cargioli, Claudio ^a   Belli, Simone ^a   Cotugno, Biagio ^a   Di Paolo, Luca ^a   Pini, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Parenteral treatment; Psychomotor agitation; Rapid tranquilization; Respiratory depression; Safety; Tolerability; Torsade de pointe; Treatment guidelines

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CHLORPROMAZINE; DIAZEPAM; DROPERIDOL; HALOPERIDOL; LITHIUM SALT; LORAZEPAM; MIDAZOLAM; MOOD STABILIZER; OLANZAPINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; ATAXIA; CARDIOVASCULAR DISEASE; DEPRESSIVE PSYCHOSIS; DOCTOR PATIENT RELATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; FALLING; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; MANIA; PERSONALITY DISORDER; PHARMACOLOGICAL PROCEDURES; PRACTICE GUIDELINE; PSYCHOSIS; QT PROLONGATION; RESPIRATION DEPRESSION; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SHORT SURVEY; SIDE EFFECT; SYSTEMATIC REVIEW; TORSADE DES POINTES;

EID: 84877709780     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00026     Document Type: Short Survey

References (57)

1. Ahmed, U., Jones, H., and Adams, C. E. (2010). Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst. Rev. 14:CD007445. doi:10.1002/14651858.CD007445
2. Alexander, J., Tharyan, P., Adams, C., John, T., Mol, C., and Philip, J. (2004). Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting. Prag-matic randomized trial of intramus-cular lorazepam v. haloperidol plus promethazine. Br. J. Psychiatry 185, 63-69.
3. Al-Khatib, S. M., LaPointe, N., Kramer, J. M., and Califf, R. M. (2003). What clinicians should know about the QT interval. JAMA. 289, 2120-2127.
4. Allen, M. H. (2000). Managing the agi-tated psychotic patient: a reappraisal of the evidence. J. Clin. Psychiatry 61(Suppl. 14), 11-20.
5. Allen, M. H., Currier, G. W., Carpenter, D., Ross, R. W., and Docherty, J. P. (2005). Expert consensus panel for behavioral emergencies 2005. The expert consensus guideline series -treatment of behavioral emergencies 2005. J. Psychiatr. Pract. 11(Suppl. 1), 5-108. quiz 110-112.
6. Allen, M. H., Currier, G. W., Hughes, D. H., Reyes-Harde, M., and Docherty, J. P. (2001). Expert consensus panel for behavioral emergencies: the expert consensus guideline series. Treatment of behavioral emergen-cies. Postgrad. Med. (Spec No):1-88; quiz 89-90.
7. Altose, M. D., and Hudgel, D. W. (1986). The pharmacology of respiratory depressants and stimulants. Clin. Chest Med. 7, 481-494.
8. Arcangeli, A., Antonelli, M., Mignani, V., and Sandroni, C. (2005). Seda-tion in PACU: the role of benzo-diazepines. Curr. Drug Targets 6, 745-748.
9. Battaglia, J. (2005). Pharmacological management of acute agitation. Drugs 65, 1207-1222.
10. Battaglia, J., Lindborg, S. R., Alaka, K., Meehan, K., and Wright, P. (2003). Calming versus sedative effects of intramuscular olanzapine in agi-tated patients. Am. J. Emerg. Med. 21, 192-198.
11. Boomsma, M. M., Mengels, O., and van Olden, R. W. (2006). Risks associ-ated with parenteral treatment of acute agitation. Tijdschr. Psychiatr. 48, 135-139.
12. Bourdinaud, V., and Pochard, F. (2003). Survey of management methods for patients in a state of agita-tion at admission and emergency departments in France. Encephale 29, 89-98.
13. Brice, J. H., Pirrallo, R. G., Racht, E., Zachariah, B. S., and Krohmer, J. (2003). Management of the vio-lent patient. Prehosp. Emerg. Care 7, 48-55.
14. Cawley, M. J. (2001). Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 21, 1140-1144.
15. Chan, E. W., Taylor, D. M., Knott, J. C., and Kong, D. C. (2011). Variation in the management of hypo-thetical cases of acute agitation in Australasian emergency depart-ments. Emerg. Med. Australas. 23, 23-32.
16. De Fruyt, J., and Demyttenaere, K. (2004). Rapid tranquilization: new approaches in the emergency treat-ment of behavioral disturbances. Eur. Psychiatry 19, 243-249.
17. Denaut, M., Yernault, J. C., and De Coster, A. (1974/1975). Doubleblind comparison of the respiratory effects of parenteral lorazepam and diazepam in patients with chronic obstructive lung dis-ease. Curr. Med. Res. Opin. 2, 611-615.
18. Dubin, W. R., and Feld, J. A. (1989). Rapid tranquilization of the violent patient. Am. J. Emerg. Med. 7, 313-320.
19. Ebmeier, K. P., Cavanagh, J., Clark, S., Dougall, N., Power, M., Reid, I., et al. (2005). Scottish Intercollegiate Guidelines Network #82: Bipolar Affective Disorder.
20. Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Moller, H. J., et al. (2005). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry 6, 132-191.
21. Feifel, D. (2000). Rationale and guide-lines for the inpatient treatment of acute psychosis. J. Clin. Psychiatry 61(Suppl. 14), 27-32.
22. Ferrier, N. (2006). National Collab-orating Centre for Mental Health (UK). Leicester: British Psychologi-cal Society.
23. Fruensgaard, K. (1978). Parenteral treatment of acute psychotic patients with agitation: a review. Curr. Med. Res. Opin. 5, 593-600.
24. Gillies, D., Beck, A., McCloud, A., Rathbone, J., and Gillies, D. (2005). Benzodiazepines alone or in com-bination with antipsychotic drugs for acute psychosis. Cochrane Database Syst. Rev. 19:CD003079. doi:10.1002/14651858.CD003079
25. Goodman, L. S., Gilman, A., and Brun-ton, L. L. (2006). Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th Edn. New York: McGraw-Hill.
26. Grunze, H., Kasper, S., Goodwin, G., Bowden, C., Baldwin, D., Licht, R. W., et al. (2003). WFSBP Task Force on Treatment Guidelines for Bipolar Disorders; The World Fed-eration of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipo-lar disorders, Part II: treatment of mania. World J. Biol. Psychiatry 4, 5-13.
27. Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Moller, H. J., et al. (2009). The World Federa-tion of Societies of Biological Psy-chiatry (WFSBP) Guidelines for the biological treatment of bipolar dis-orders: update 2009 on the treat-ment of acute mania. World J. Biol. Psychiatry 10, 85-116.
28. Hassaballa,H.A.,and Balk,R.A. (2003). Torsade de pointes associated with the administration of intravenous haloperidol: a review of the liter-ature and practical guidelines for use. Expert Opin. Drug Saf. 2, 543-547.
29. Hoehns, J. D., Stanford, R. H., Ger-aets, D. R., Skelly, K. S., Lee, H. C., and Gaul, B. L. (2001). Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy 21, 871-883.
30. Huf, G., Alexander, J., and Allen, M. H. (2005). Haloperidol plus promet-hazine for psychosis induced aggres-sion. Cochrane Database Syst. Rev. 25.
31. Hunt, N., and Stern, T. A. (1995). The association between intravenous haloperidol and Torsades de Pointes. Three cases and a liter-ature review. Psychosomatics 36, 541-549.
32. Jackson, T., Ditmanson, L., and Phibbs, B. (1997). Torsade de pointes and low-dose oral haloperi-dol. Arch. Intern. Med. 157, 2013-2015.
33. Jedeikin, R., Menutti, D., Bruderman, I., and Hoffman, S. (1985). Prolonged respiratory center depression after alcohol and benzodiazepines. Chest 87, 262-264.
34. Karagianis, J. L., Dawe, I. C., Thakur, A., Bégin, S., Raskin, J., and Roy-chowdhury, S. M. (2001). Rapid tranquilization with olanzapine in acute psychosis: a case series. J. Clin. Psychiatry 62(Suppl. 2), 12-16.
35. Lindenmayer, J. P. (2000). The patho-physiology of agitation. J. Clin. Psy-chiatry 61(Suppl. 14), 5-10.
36. Mantovani, C., Migon, M. N., Alheira, F. V., and Del-Ben, C. M. (2010). Management of the violent or agi-tated patient. Rev. Bras. Psiquiatr. 32(Suppl. 2), S96-S103.
37. Marder, S. R. (2006). A review of agi-tation in mental illness: treatment guidelines and current therapies. J. Clin. Psychiatry 67(Suppl. 10), 13-21.
38. Meyer-Massetti, C., Cheng, C. M., Sharpe, B. A., Meier, C. R., and Guglielmo, B. J. (2010). The FDA extended warning for intra-venous haloperidol and torsades de pointes: how should institu-tions respond? J. Hosp. Med. 5, E8-E16.
39. Mintzer, J. E. (2006). Introduction: the clinical impact of agitation in var-ious psychiatric disorders: manage-ment consensus and controversies. J. Clin. Psychiatry 67(Suppl. 10), 3-5.
40. Muench, J., and Hamer, A. M. (2010). Adverse effects of antipsychotic medications. Am. Fam. Physician 81, 617-622.
41. Nordt, S. P., and Clark, R. F. (1997). Midazolam: a review of therapeutic uses and toxicity. J. Emerg. Med. 15, 357-365.
42. Peppers, M. P. (1996). Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy 16, 49-57.
43. Riker, R. R., and Fraser, G. L. (2009). Altering intensive care sedation paradigms to improve patient outcomes. Crit. Care Clin. 25, 527-538.
44. Smith, M. T., Eadie, M. J., and Brophy, T. O. (1981). The pharmacokinetics of midazolam in man. Eur. J. Clin. Pharmacol. 19, 271-278. PMCID: 6116606.
45. Spain, D., Crilly, J., Whyte, I., Jenner, L., Carr, V., and Baker, A. (2008). Safety and effectiveness of high-dose mida-zolam for severe behavioural distur-bance in an emergency department with suspected psychostimulant-affected patients. Emerg. Med. Aus-tralas. 20, 112-120.
46. Swanson, J., Hozler, C., and Ganju, V. R. (1990). Violence and psy-chiatric disorder in the com-munity: evidence from the epi-demiologic catchment area surveys. Hosp. Community Psychiatry 41, 761-770.
47. Tan, H. H., Hoppe, J., and Heard, K. (2009). A systematic review of cardiovascular effects following atypical antipsychotic medication overdose. Am. J. Emerg. Med. 27, 607-616.
48. Tardiff, K., and Sweillam, A. (1982). Assaultive behavior among chronic inpatients. Am. J. Psychiatry 139, 212-215.
49. Taylor, D., Paton, C., and Kapur, S. (2009). "Acutely disturbed/violent behaviour," in The Maudsley Pre-scribing Guidelines, 10th Edn. eds D. Taylor, C. Paton, and S. Kapur (London: Informa Healthcare), 417-424.
50. Tisdale, J. E., Rasty, S., Padhi, I. D., Sharma, N. D., and Rosman, H. (2001). The effect of intravenous haloperidol on QT interval dis-persion in critically ill patients: comparison with QT interval pro-longation for assessment of risk of Torsades de Pointes. J. Clin. Pharmacol. 41, 1310-1318. Erratum in: J. Clin. Pharmacol. (2002) 42, 577-579.
51. Wilson, K. C., Reardon, C., and Farber, H. W. (2000). Propylene glycol tox-icity [letter]. N. Engl. J. Med. 343, 815.
52. Wilson, K. C., Reardon, C., Theodore, A. C., and Farber, H. W. (2005). Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, obser-vational pilot study. Chest 128, 1674-1681.
53. Wilson, M. P., MacDonald, K., Vilke, G. M., and Feifel, D. (2012a). Poten-tial complications of combining intramuscular olanzapine with ben-zodiazepines in emergency depart-ment patients. J. Emerg. Med. 43, 889-896.
54. Wilson, M. P., MacDonald, K., Vilke, G. M., and Feifel, D. (2012b). A com-parison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emer-gency department patients with acute agitation. J. Emerg. Med. 43, 790-797.
55. Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., Mac-Queen, G., McIntyre, R., et al. (2005). Canadian Network for Mood and Anxiety Treatments; Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: con-sensus and controversies. Bipolar Disord. 7(Suppl. 3), 5-69.
56. Zar, T., Graeber, C., and Perazella, M. A. (2007). Recognition, treatment, and prevention of propylene glycol toxicity. Semin. Dial. 20, 217-219.
57. Zimbroff, D. L. (2008). Pharmacologi-cal control of acute agitation: focus on intramuscular preparations. CNS Drugs 22, 199-212.